COVID-19, community trials, and inclusion
Lancet
.
2021 Mar 20;397(10279):1036-1037.
doi: 10.1016/S0140-6736(21)00661-9.
Authors
Paramjit S Gill
1
,
Shoba Poduval
2
,
Jarnail S Thakur
3
,
Romaina Iqbal
4
Affiliations
1
Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK. Electronic address: p.gill.1@warwick.ac.uk.
2
UCL eHealth Unit, Department of Primary Care and Population Health, University College London, London, UK.
3
Department of Community Medicine and School of Public Health, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
4
Department of Community Health Sciences, Aga Khan University. Karachi, Pakistan.
PMID:
33743853
PMCID:
PMC7972324
DOI:
10.1016/S0140-6736(21)00661-9
No abstract available
Publication types
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Azithromycin*
COVID-19 Drug Treatment*
Humans
SARS-CoV-2
United Kingdom
Substances
Azithromycin